Motus GI Holdings Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Motus GI Holdings te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.0%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Motus GI regains compliance with minimum bid price requirement

Aug 11

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Jul 25

Motus GI starts enrollment in Pure-Vu System EU study

Jun 16

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System

Apr 30

Here's Why Motus GI Holdings (NASDAQ:MOTS) Can Manage Its Debt Despite Losing Money

Mar 02

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Motus GI Holdings onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:MOTS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2024	0	-16	-8	-8	N/A
12/31/2023	0	-13	-11	-11	N/A
9/30/2023	0	-14	-13	-13	N/A
6/30/2023	1	-16	-15	-15	N/A
3/31/2023	1	-18	-17	-17	N/A
12/31/2022	1	-19	-18	-17	N/A
9/30/2022	1	-20	-18	-17	N/A
6/30/2022	0	-20	-17	-17	N/A
3/31/2022	0	-19	-15	-15	N/A
12/31/2021	0	-25	-15	-14	N/A
9/30/2021	0	-25	-14	-13	N/A
6/30/2021	0	-24	-13	-13	N/A
3/31/2021	0	-24	-15	-14	N/A
12/31/2020	0	-19	-17	-17	N/A
9/30/2020	0	-21	-20	-20	N/A
6/30/2020	0	-22	-22	-21	N/A
3/31/2020	0	-23	-22	-22	N/A
12/31/2019	0	-23	-20	-20	N/A
9/30/2019	0	-23	-20	-19	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	0	-21	-18	-17	N/A
12/31/2018	0	-22	-15	-15	N/A
9/30/2018	0	-20	-14	-13	N/A
6/30/2018	0	-18	-13	-13	N/A
3/31/2018	0	-18	-12	-12	N/A
12/31/2017	N/A	-13	N/A	-10	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-7	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van MOTS boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van MOTS naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van MOTS naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van MOTS naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van MOTS naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MOTS naar verwachting over 3 jaar hoog zal zijn

Motus GI Holdings Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus EPS estimates upgraded to US$2.48 loss

Price target increased by 58% to US$10.00

Consensus revenue estimates fall by 22%

Price target decreased to US$11.00

Recent updates

Motus GI Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $4.99972 million.

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

New minor risk - Share price stability

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$2.48 loss

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

Price target increased by 58% to US$10.00

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI regains compliance with minimum bid price requirement

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Price target decreased to US$1.43

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Price target decreased to US$1.73

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Price target decreased to US$1.86

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Consensus forecasts updated

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

Motus GI starts enrollment in Pure-Vu System EU study

Consensus forecasts updated

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Price target decreased to US$2.24

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System